Secondly, the expression of TFEB was restored after ponatinib treatment, suggesting that ponatinib played a therapeutic role in NASH by upregulating TFEB, thereby facilitating the lysosomal clearance of autophagosomes. The gene discussed is TFEB; the disease is metabolic dysfunction-associated steatohepatitis.